Compound ID | 261
OPT-382
Class: Aminoglycoside
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Protein synthesis inhibitor |
| Target Pathogen: | Active against Pseudomonas aeruginosa |
| Description: | Reduced acute toxicity in mouse infection model; Sucheck SJ, Yao S, Sgarbi PWM, et al. Discovery of novel aminoglycosides through OPopS glycosylation. 43rd-ICAAC 2003;272 |
| Institute where first reported: | Optimer Pharmaceuticals, Singapore |
| Year first mentioned: | 2003 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| Reason dropped: | From the same program as fidaxomycin where 4 lead products were identified, with the exception of fidaxomycin, everything was discontinued. |
| External links: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.